{"DataElement":{"publicId":"7409539","version":"1","preferredName":"Surgical Tumor Tissue Anticipated CPTAC Neoplasm Type","preferredDefinition":"The anticipated CPTAC tissue type assigned to a malignant neoplasm sample that was surgically removed from an organ.","longName":"7409538v1.0:7385481v1.0","context":"OCCPR","contextVersion":"1","DataElementConcept":{"publicId":"7409538","version":"1","preferredName":"Surgical Tumor Tissue Anticipated CPTAC Neoplasm","preferredDefinition":"A diagnostic or treatment procedure performed by manual and/or instrumental means, often involving an incision and the removal or replacement of a diseased organ or tissue; of or relating to or involving or used in surgery or requiring or amenable to treatment by surgery._A tumor sample, or entire tumor that is removed for microscopic examination._Considered likely or probable; anticipated._A national effort to accelerate the understanding of the molecular basis of cancer through the application of large-scale proteome and genome analysis, or proteogenomics._A benign or malignant tissue growth resulting from uncontrolled cell proliferation. Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant cells exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia. Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias.","longName":"7409535v1.0:7409536v1.0","context":"OCCPR","contextVersion":"1","ObjectClass":{"publicId":"7409535","version":"1","preferredName":"Surgical Procedure Tumor Tissue","preferredDefinition":"A diagnostic or treatment procedure performed by manual and/or instrumental means, often involving an incision and the removal or replacement of a diseased organ or tissue; of or relating to or involving or used in surgery or requiring or amenable to treatment by surgery.:A tumor sample, or entire tumor that is removed for microscopic examination.","longName":"C15329:C18009","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Surgical Procedure","conceptCode":"C15329","definition":"A diagnostic or treatment procedure performed by manual and/or instrumental means, often involving an incision and the removal or replacement of a diseased organ or tissue; of or relating to or involving or used in surgery or requiring or amenable to treatment by surgery.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Tumor Tissue Sample","conceptCode":"C18009","definition":"Tissue sample that contains an abnormal cellular infiltrate forming a solid mass. The abnormal cellular component can be benign or malignant. Tumor samples are obtained for microscopic examination and/or molecular analysis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"ADE3BA57-4CCB-550B-E053-4EBD850A026F","latestVersionIndicator":"Yes","beginDate":"2020-08-27","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-08-27","modifiedBy":"ONEDATA","dateModified":"2020-08-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"7409536","version":"1","preferredName":"Expected Clinical Proteomic Tumor Analysis Consortium Neoplasm","preferredDefinition":"Considered likely or probable; anticipated.:A national effort to accelerate the understanding of the molecular basis of cancer through the application of large-scale proteome and genome analysis, or proteogenomics.:A benign or malignant tissue growth resulting from uncontrolled cell proliferation. Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant cells exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia. Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias.","longName":"C25501:C157175:C3262","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Expected","conceptCode":"C25501","definition":"Considered likely or probable; anticipated.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Clinical Proteomic Tumor Analysis Consortium","conceptCode":"C157175","definition":"A national effort to accelerate the understanding of the molecular basis of cancer through the application of large-scale proteome and genome analysis, or proteogenomics.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Neoplasm","conceptCode":"C3262","definition":"A benign or malignant tissue growth resulting from uncontrolled cell proliferation. Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant cells exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia. Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"ADE3BA57-4CDD-550B-E053-4EBD850A026F","latestVersionIndicator":"Yes","beginDate":"2020-08-27","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-08-27","modifiedBy":"ONEDATA","dateModified":"2020-08-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008547","version":"1","preferredName":"Specimen Characteristics","preferredDefinition":"attributes of a patient's laboratory sample, including the source, condition, and fixative.","longName":"SPEC_CHAR","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22908C4-638F-4A74-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"ADE3BA57-4CEE-550B-E053-4EBD850A026F","latestVersionIndicator":"Yes","beginDate":"2020-08-27","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-08-27","modifiedBy":"KNABLEJ","dateModified":"2021-01-26","changeDescription":"1/26/21 jk Released per SME (NGM) review and approval. 8/27/20 jk created for Solid tumor procurement CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"7385481","version":"1","preferredName":"CPTAC Tumor Type","preferredDefinition":"A national effort to accelerate the understanding of the molecular basis of cancer through the application of large-scale proteome and genome analysis, or proteogenomics._An abnormal mass of tissue that results when cells divide more than they should or do not die when they should. Neoplasms may be benign (not cancer), or malignant (cancer)._Something distinguishable as an identifiable class based on common qualities.","longName":"7385481v1.0","context":"OCCPR","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"1","maxLength":"100","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Brain: Lower Grade Glioma (LGG)","valueDescription":"Low Grade Glioma","ValueMeaning":{"publicId":"7315250","version":"1","preferredName":"Low Grade Glioma","longName":"7315250","preferredDefinition":"A grade I or grade II glioma arising from the central nervous system. This category includes pilocytic astrocytoma, diffuse astrocytoma, subependymal giant cell astrocytoma, ependymoma, oligodendroglioma, oligoastrocytoma, and angiocentric glioma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Low Grade Glioma","conceptCode":"C132067","definition":"A grade I or grade II glioma arising from the central nervous system. This category includes pilocytic astrocytoma, diffuse astrocytoma, subependymal giant cell astrocytoma, ependymoma, oligodendroglioma, oligoastrocytoma, and angiocentric glioma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A7098F74-26D6-7CC5-E053-4EBD850A4F07","latestVersionIndicator":"Yes","beginDate":"2020-06-01","endDate":null,"createdBy":"MAESKEB","dateCreated":"2020-06-01","modifiedBy":"KUMMEROA","dateModified":"2022-06-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"ACA0F8EC-0B22-0AA9-E053-4EBD850AE771","beginDate":"2020-08-11","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-08-11","modifiedBy":"ONEDATA","dateModified":"2020-08-11","deletedIndicator":"No"},{"value":"Brain: Glioblastoma Multiforme (GBM)","valueDescription":"Glioblastoma","ValueMeaning":{"publicId":"3686274","version":"1","preferredName":"Glioblastoma","longName":"3686274","preferredDefinition":"The most malignant astrocytic tumor (WHO grade IV). It is composed of poorly differentiated neoplastic astrocytes and it is characterized by the presence of cellular polymorphism, nuclear atypia, brisk mitotic activity, vascular thrombosis, microvascular proliferation and necrosis. It typically affects adults and is preferentially located in the cerebral hemispheres. It may develop from diffuse astrocytoma WHO grade II or anaplastic astrocytoma (secondary glioblastoma), but more frequently, it manifests after a short clinical history de novo, without evidence of a less malignant precursor lesion (primary glioblastoma). Two histologic variants are recognized: giant cell glioblastoma and gliosarcoma. (WHO) ","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Glioblastoma","conceptCode":"C3058","definition":"The most malignant astrocytic tumor (WHO grade 4).  It is composed of poorly differentiated neoplastic astrocytes and is characterized by the presence of cellular polymorphism, nuclear atypia, brisk mitotic activity, vascular thrombosis, microvascular proliferation, and necrosis. It typically affects adults and is preferentially located in the cerebral hemispheres. (Adapted from WHO)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D5C534CC-6FFB-BB02-E040-BB89AD4314F2","latestVersionIndicator":"Yes","beginDate":"2013-02-15","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"ACA0F8EC-0B37-0AA9-E053-4EBD850AE771","beginDate":"2020-08-11","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-08-11","modifiedBy":"ONEDATA","dateModified":"2020-08-11","deletedIndicator":"No"},{"value":"Eye: Uveal Melanoma (UVM)","valueDescription":"Uveal Melanoma","ValueMeaning":{"publicId":"3251352","version":"1","preferredName":"Uveal Melanoma","longName":"3251352","preferredDefinition":"A melanoma derived from melanocytes of the uveal tract.  It is the most common primary intraocular tumor in the United States and Western Europe.  Similar to melanoma of the skin, it is rare in Africa and Asia.  Diagnostic procedures include ophthalmoscopic exam, fluorescein angiography and ultrasound.  Treatment includes: surgical excision of the eye, iridocyclectomy and tumor resection.  Recent treatments also include radiotherapy or photo coagulation.  Classification of uveal melanomas recognizes four cell types within these tumors: epithelioid, intermediate, mixed cell, and spindle cell types.  The spindle cell type uveal melanomas are further sub-classified as spindle cell type A and spindle cell type B.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Uveal Melanoma","conceptCode":"C7712","definition":"A melanoma derived from melanocytes of the uveal tract.  It is the most common primary intraocular tumor in the United States and Western Europe.  Similar to melanoma of the skin, it is rare in Africa and Asia.  Diagnostic procedures include ophthalmoscopic exam, fluorescein angiography and ultrasound.  Treatment includes: surgical excision of the eye, iridocyclectomy and tumor resection.  Recent treatments also include radiotherapy or photo coagulation.  Classification of uveal melanomas recognizes four cell types within these tumors: epithelioid, intermediate, mixed cell, and spindle cell types.  The spindle cell type uveal melanomas are further sub-classified as spindle cell type A and spindle cell type B.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A758F49E-9ECF-73F4-E040-BB89AD430DFE","latestVersionIndicator":"Yes","beginDate":"2011-07-05","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-07-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"ACA0F8EC-0B4C-0AA9-E053-4EBD850AE771","beginDate":"2020-08-11","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-08-11","modifiedBy":"ONEDATA","dateModified":"2020-08-11","deletedIndicator":"No"},{"value":"Esophagus: Esophageal Carcinoma (ESCA)","valueDescription":"Esophageal Carcinoma","ValueMeaning":{"publicId":"5581332","version":"1","preferredName":"Esophageal Carcinoma","longName":"5581332","preferredDefinition":"A malignant epithelial tumor arising from the esophageal mucosa. Two major histologic types of esophageal carcinoma have been described: squamous cell carcinoma and adenocarcinoma. This type of cancer is associated with excessive ethanol and cigarette usage.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Esophageal Carcinoma","conceptCode":"C3513","definition":"A malignant epithelial tumor arising from the esophageal mucosa. Two major histologic types of esophageal carcinoma have been described: squamous cell carcinoma and adenocarcinoma. This type of cancer is associated with excessive ethanol and cigarette usage.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"42019733-B739-634F-E053-F662850A5A61","latestVersionIndicator":"Yes","beginDate":"2016-11-23","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2016-11-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"ACA0F8EC-0B61-0AA9-E053-4EBD850AE771","beginDate":"2020-08-11","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-08-11","modifiedBy":"ONEDATA","dateModified":"2020-08-11","deletedIndicator":"No"},{"value":"Soft Tissue: Sarcoma (SAR)","valueDescription":"Soft Tissue Sarcoma","ValueMeaning":{"publicId":"3384698","version":"1","preferredName":"Soft Tissue Sarcoma","longName":"3384698","preferredDefinition":"A malignant mesenchymal neoplasm arising from muscle tissue, adipose tissue, blood vessels, fibrous tissue, or other supportive tissues excluding the bones.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Soft Tissue Sarcoma","conceptCode":"C9306","definition":"A malignant neoplasm arising from muscle tissue, adipose tissue, blood vessels, fibrous tissue, or other supportive tissues excluding the bones.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9A3DDB0-75C8-1600-E040-BB89AD432CFF","latestVersionIndicator":"Yes","beginDate":"2012-02-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AC9EAAE3-68D6-58C2-E053-4EBD850A8F9D","beginDate":"2020-08-11","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-08-11","modifiedBy":"ONEDATA","dateModified":"2020-08-11","deletedIndicator":"No"},{"value":"Lung: Adenocarcinoma (LUAD)","valueDescription":"Lung Adenocarcinoma","ValueMeaning":{"publicId":"3106713","version":"1","preferredName":"Lung Adenocarcinoma","longName":"3106713","preferredDefinition":"A carcinoma characterized by the presence of malignant glandular epithelial cells.  There is a male predilection with a male to female ratio of 2:1.  Usually lung adenocarcinoma is asymptomatic and is identified through screening studies or as an incidental radiologic finding.  If clinical symptoms are present they include shortness of breath, cough, hemoptysis, chest pain, and fever.  Tobacco smoke is a known risk factor.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lung Adenocarcinoma","conceptCode":"C3512","definition":"A carcinoma that arises from the lung and is characterized by the presence of malignant glandular epithelial cells.  There is a male predilection with a male to female ratio of 2:1.  Usually lung adenocarcinoma is asymptomatic and is identified through screening studies or as an incidental radiologic finding.  If clinical symptoms are present they include shortness of breath, cough, hemoptysis, chest pain, and fever.  Tobacco smoke is a known risk factor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"883834AB-0D4B-C6A6-E040-BB89AD431A8D","latestVersionIndicator":"Yes","beginDate":"2010-06-04","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-06-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AC9FA288-FDC6-6036-E053-4EBD850AF7DB","beginDate":"2020-08-11","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-08-11","modifiedBy":"ONEDATA","dateModified":"2020-08-11","deletedIndicator":"No"},{"value":"Lung: Squamous Cell Carcinoma (LSCC)","valueDescription":"Squamous Cell Lung Carcinoma","ValueMeaning":{"publicId":"2956083","version":"1","preferredName":"Squamous Cell Lung Carcinoma","longName":"2956083","preferredDefinition":"A carcinoma arising from malignant squamous bronchial epithelial cells and characterized by the presence of keratinization and/or intercellular bridges.  Cigarette smoking and arsenic exposure are strongly associated with squamous cell lung carcinoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lung Squamous Cell Carcinoma","conceptCode":"C3493","definition":"A carcinoma arising from squamous bronchial epithelial cells. It may be keratinizing or non-keratinizing. Keratinizing squamous cell carcinoma is characterized by the presence of keratinization, pearl formation, and/or intercellular bridges. Non-keratinizing squamous cell carcinoma is characterized by the absence of keratinization, pearl formation, and intercellular bridges. Cigarette smoking and arsenic exposure are strongly associated with squamous cell lung carcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"76EBECE2-B835-A0E2-E040-BB89AD435984","latestVersionIndicator":"Yes","beginDate":"2009-10-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-10-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AC9FA288-FDDB-6036-E053-4EBD850AF7DB","beginDate":"2020-08-11","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-08-11","modifiedBy":"ONEDATA","dateModified":"2020-08-11","deletedIndicator":"No"},{"value":"Skin: Cutaneous Melanoma (CM)","valueDescription":"Cutaneous Melanoma","ValueMeaning":{"publicId":"2798718","version":"1","preferredName":"Cutaneous Melanoma","longName":"2798718","preferredDefinition":"A primary melanoma arising from atypical melanocytes in the skin.  Precursor lesions include acquired and congenital melanocytic nevi, and dysplastic nevi.  Several histologic variants have been recognized, including superficial spreading melanoma, acral lentiginous melanoma, nodular melanoma, and lentigo maligna melanoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cutaneous Melanoma","conceptCode":"C3510","definition":"A primary melanoma arising from atypical melanocytes in the skin.  Precursor lesions include acquired and congenital melanocytic nevi, and dysplastic nevi.  Several histologic variants have been recognized, including superficial spreading melanoma, acral lentiginous melanoma, nodular melanoma, and lentigo maligna melanoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5B4B7C4C-6A82-156F-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-11-09","endDate":null,"createdBy":"UMLLOADER_SEERHG","dateCreated":"2008-11-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AC9FA288-FDF0-6036-E053-4EBD850AF7DB","beginDate":"2020-08-11","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-08-11","modifiedBy":"ONEDATA","dateModified":"2020-08-11","deletedIndicator":"No"},{"value":"Head and Neck: Squamous Cell Carcinoma (HNSCC)","valueDescription":"Head and Neck Squamous Cell Carcinoma","ValueMeaning":{"publicId":"4722786","version":"1","preferredName":"Head and Neck Squamous Cell Carcinoma","longName":"4722786","preferredDefinition":"A squamous cell carcinoma that arises from any of the following anatomic sites: lip and oral cavity, nasal cavity, paranasal sinuses, pharynx, larynx, and salivary glands.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Head and Neck Squamous Cell Carcinoma","conceptCode":"C34447","definition":"A squamous cell carcinoma that arises from any of the following anatomic sites: lip and oral cavity, nasal cavity, paranasal sinuses, pharynx, larynx, and salivary glands.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F8A7B21-23F6-7895-E050-BB89AD43579D","latestVersionIndicator":"Yes","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AC9FA288-FE05-6036-E053-4EBD850AF7DB","beginDate":"2020-08-11","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-08-11","modifiedBy":"ONEDATA","dateModified":"2020-08-11","deletedIndicator":"No"},{"value":"Pancreas: Pancreatic Ductal Adenocarcinoma (PDA)","valueDescription":"Pancreatic Ductal Adenocarcinoma","ValueMeaning":{"publicId":"2581788","version":"1","preferredName":"Pancreatic Ductal Adenocarcinoma","longName":"2581788","preferredDefinition":"A carcinoma occurring almost exclusively in adults that probably arises from the pancreatic duct epithelium.  Most pancreatic carcinomas are ductal adenocarcinomas of which about two-thirds involve the head, with the remainder in the body and tail of the pancreas.  The patients are usually over 50 years of age.  Pain, jaundice, and loss of weight are the most common manifestations.  Ductal adenocarcinomas usually grow rapidly and are discovered after they have already spread beyond the pancreas.  Grossly, ductal adenocarcinomas are firm and poorly defined masses.  Microscopically, most ductal adenocarcinomas are characterized by well-developed glandular structures embedded in a desmoplastic stroma.  Ductal adenocarcinomas are fatal in the vast majority of cases (WHO 2000). --2002","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pancreatic Ductal Adenocarcinoma","conceptCode":"C9120","definition":"An infiltrating adenocarcinoma that arises from the epithelial cells of the pancreas.  It affects males more often than females and the patients are usually over 50 years of age.  Microscopically it is characterized by the presence of glandular (ductal) differentiation and desmoplastic stroma formation.  Signs and symptoms include pain, loss of weight, and jaundice.  It grows rapidly and is usually detected after it has metastasized to other anatomic sites.  The prognosis is usually poor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0C89-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-11-10","endDate":null,"createdBy":"SCHMANDL","dateCreated":"2006-11-10","modifiedBy":"ONEDATA","dateModified":"2006-11-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AC9FA288-FE1A-6036-E053-4EBD850AF7DB","beginDate":"2020-08-11","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-08-11","modifiedBy":"ONEDATA","dateModified":"2020-08-11","deletedIndicator":"No"},{"value":"Cervix: Cervical Squamous Cell Carcinoma or Endocervical Adenocarcinoma (CESC)","valueDescription":"Exocervical Carcinoma And Endocervical Carcinoma","ValueMeaning":{"publicId":"7385483","version":"1","preferredName":"Exocervical Carcinoma And Endocervical Carcinoma","longName":"7385483","preferredDefinition":"A carcinoma that arises from the squamous epithelium of the exocervix.: An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.: An adenocarcinoma characterized by the presence of malignant glandular epithelium resembling the endocervical epithelium.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Exocervical Carcinoma","conceptCode":"C7453","definition":"A carcinoma that arises from the squamous epithelium of the exocervix.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"And","conceptCode":"C37912","definition":"An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Endocervical Carcinoma","conceptCode":"C28327","definition":"A carcinoma that arises from the endocervix.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"ACA0B1F3-8008-4383-E053-4EBD850A04CC","latestVersionIndicator":"Yes","beginDate":"2020-08-11","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-08-11","modifiedBy":"ONEDATA","dateModified":"2020-08-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"ACA0B1F3-8021-4383-E053-4EBD850A04CC","beginDate":"2020-08-11","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-08-11","modifiedBy":"ONEDATA","dateModified":"2020-08-11","deletedIndicator":"No"},{"value":"Thyroid: Thyroid Carcinoma (THCA)","valueDescription":"Thyroid Gland Carcinoma","ValueMeaning":{"publicId":"5581344","version":"1","preferredName":"Thyroid Gland Carcinoma","longName":"5581344","preferredDefinition":"A carcinoma arising from the thyroid gland. It is usually an adenocarcinoma and includes the following main subtypes: follicular, papillary, medullary, poorly differentiated, and anaplastic.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Thyroid Gland Carcinoma","conceptCode":"C4815","definition":"A carcinoma arising from the thyroid gland. It includes the following main subtypes: follicular, papillary, medullary, poorly differentiated, and anaplastic carcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"42019733-B8E8-634F-E053-F662850A5A61","latestVersionIndicator":"Yes","beginDate":"2016-11-23","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2016-11-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"ACA0B1F3-8035-4383-E053-4EBD850A04CC","beginDate":"2020-08-11","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-08-11","modifiedBy":"ONEDATA","dateModified":"2020-08-11","deletedIndicator":"No"},{"value":"Prostate: Prostate Adenocarcinoma (PRAD)","valueDescription":"Prostate Adenocarcinoma","ValueMeaning":{"publicId":"3320078","version":"1","preferredName":"Prostate Adenocarcinoma","longName":"3320078","preferredDefinition":"An adenocarcinoma arising from the prostate gland. It is one of the most common malignant tumors afflicting men. The majority of adenocarcinomas arise in the peripheral zone and a minority occurs in the central or the transitional zone of the prostate gland. Grading of prostatic adenocarcinoma predicts disease progression and correlates with survival. Several grading systems have been proposed, of which the Gleason system is the most commonly used. Gleason sums of 2 to 4 represent well-differentiated disease, 5 to 7 moderately differentiated disease and 8 to 10 poorly differentiated disease. Prostatic-specific antigen (PSA) serum test is widely used as a screening test for the early detection of prostatic adenocarcinoma. Treatment options include radical prostatectomy, radiation therapy, androgen ablation and cryotherapy. Watchful waiting or surveillance alone is an option for older patients with low-grade or low-stage disease.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prostate Adenocarcinoma","conceptCode":"C2919","definition":"An adenocarcinoma arising from the prostate gland.  It is one of the most common malignant tumors afflicting men.  The majority of adenocarcinomas arise in the peripheral zone and a minority occurs in the central or the transitional zone of the prostate gland.  Grading of prostatic adenocarcinoma predicts disease progression and correlates with survival.  Several grading systems have been proposed, of which the Gleason system is the most commonly used.  Gleason sums of 2 to 4 represent well-differentiated disease, 5 to 7 moderately differentiated disease and 8 to 10 poorly differentiated disease.  Prostatic-specific antigen (PSA) serum test is widely used as a screening test for the early detection of prostatic adenocarcinoma.  Treatment options include radical prostatectomy, radiation therapy, androgen ablation and cryotherapy.  Watchful waiting or surveillance alone is an option for older patients with low-grade or low-stage disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B31E33BB-6E5A-7D8D-E040-BB89AD431F32","latestVersionIndicator":"Yes","beginDate":"2011-12-02","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-12-02","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"ACA0B1F3-804A-4383-E053-4EBD850A04CC","beginDate":"2020-08-11","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-08-11","modifiedBy":"ONEDATA","dateModified":"2020-08-11","deletedIndicator":"No"},{"value":"Bile duct/Liver: Cholangiocarcinoma (CHOL)","valueDescription":"Cholangiocarcinoma","ValueMeaning":{"publicId":"4722725","version":"1","preferredName":"Cholangiocarcinoma","longName":"4722725","preferredDefinition":"A carcinoma that arises from the intrahepatic biliary tree (intrahepatic cholangiocarcinoma) or from the junction, or adjacent to the junction, of the right and left hepatic ducts (hilar cholangiocarcinoma). Grossly, the malignant lesions are solid, nodular, and grayish. Morphologically, the vast majority of cases are adenocarcinomas. Signs and symptoms include malaise, weight loss, right upper quadrant abdominal pain, and night sweats. Early detection is difficult and the prognosis is generally poor.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cholangiocarcinoma","conceptCode":"C4436","definition":"A carcinoma that arises from the intrahepatic bile ducts, the hepatic ducts, or the common bile duct distal to the insertion of the cystic duct. The vast majority of tumors are adenocarcinomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F8A7B21-1D7B-7895-E050-BB89AD43579D","latestVersionIndicator":"Yes","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"ACA0B1F3-805F-4383-E053-4EBD850A04CC","beginDate":"2020-08-11","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-08-11","modifiedBy":"ONEDATA","dateModified":"2020-08-11","deletedIndicator":"No"},{"value":"Liver: Hepatocellular Carcinoma (LIHC)","valueDescription":"Hepatocellular Carcinoma","ValueMeaning":{"publicId":"2573454","version":"1","preferredName":"Hepatocellular Carcinoma","longName":"2573454","preferredDefinition":"A malignant tumor that arises from hepatocytes. Hepatocellular carcinoma is relatively rare in the United States but very common in all African countries south of the Sahara and in Southeast Asia. Most cases are seen in patients over the age of 50 years, but this tumor can also occur in younger individuals and even in children. Hepatocellular carcinoma is more common in males than females and is associated with hepatitis B, hepatitis C, chronic alcohol abuse and cirrhosis. Serum elevation of alpha-fetoprotein occurs in a large percentage of patients with hepatocellular carcinoma. Grossly, hepatocellular carcinoma may present as a single mass, as multiple nodules, or as diffuse liver involvement. Microscopically, there is a wide range of differentiation from tumor to tumor (well differentiated to poorly differentiated tumors). Hepatocellular carcinomas quickly metastasize to regional lymph nodes and lung. The overall median survival of untreated liver cell carcinoma is about 4 months. The most effective treatment of hepatocellular carcinoma is complete resection of the tumor. Lately, an increasing number of tumors have been treated with liver transplantation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hepatocellular Carcinoma","conceptCode":"C3099","definition":"A malignant tumor that arises from hepatocytes. Hepatocellular carcinoma is relatively rare in the United States but very common in all African countries south of the Sahara and in Southeast Asia. Most cases are seen in patients over the age of 50 years, but this tumor can also occur in younger individuals and even in children. Hepatocellular carcinoma is more common in males than females and is associated with hepatitis B, hepatitis C, chronic alcohol abuse and cirrhosis. Serum elevation of alpha-fetoprotein occurs in a large percentage of patients with hepatocellular carcinoma. Grossly, hepatocellular carcinoma may present as a single mass, as multiple nodules, or as diffuse liver involvement. Microscopically, there is a wide range of differentiation from tumor to tumor (well differentiated to poorly differentiated tumors). Hepatocellular carcinomas quickly metastasize to regional lymph nodes and lung. The overall median survival of untreated liver cell carcinoma is about 4 months. The most effective treatment of hepatocellular carcinoma is complete resection of the tumor. Lately, an increasing number of tumors have been treated with liver transplantation.","evsSource":"UMLS_CUI","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-EBFB-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-15","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-03-15","modifiedBy":"CHILLIJ","dateModified":"2007-03-27","changeDescription":"03/27/2007 - Updated with NCI Thesaurus definition (abbreviated version.)","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"ACA0B1F3-8074-4383-E053-4EBD850A04CC","beginDate":"2020-08-11","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-08-11","modifiedBy":"ONEDATA","dateModified":"2020-08-11","deletedIndicator":"No"},{"value":"Stomach: Stomach Adenocarcinoma (STAD)","valueDescription":"Gastric Adenocarcinoma","ValueMeaning":{"publicId":"3206052","version":"1","preferredName":"Gastric Adenocarcinoma","longName":"3206052","preferredDefinition":"An adenocarcinoma arising from the stomach glandular epithelium. Gastric adenocarcinoma is primarily a disease of older individuals, most commonly develops after a long period of atrophic gastritis and is strongly associated with Helicobacter pylori infection. The lack of early symptoms often delays the diagnosis of gastric cancer. The majority of patients present with advanced tumors which have poor rates of curability. Microscopically, two important histologic types of gastric adenocarcinoma are recognized: the intestinal and diffuse type. The overall prognosis of gastric adenocarcinomas is poor, even in patients who receive a \"curative\" resection (adapted from Sternberg's Surgical Pathology, 3rd ed., 1999).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gastric Adenocarcinoma","conceptCode":"C4004","definition":"An adenocarcinoma arising from the stomach glandular epithelium. Gastric adenocarcinoma is primarily a disease of older individuals.  It most commonly develops after a long period of atrophic gastritis and is strongly associated with Helicobacter pylori infection. The lack of early symptoms often delays the diagnosis of gastric cancer. The majority of patients present with advanced tumors which have poor rates of curability. Microscopically, two important histologic types of gastric adenocarcinoma are recognized: the intestinal and diffuse type. The overall prognosis of gastric adenocarcinomas is poor, even in patients who receive a \"curative\" resection (adapted from Sternberg's Surgical Pathology, 3rd ed., 1999).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F03F2AF-4F8F-0E9A-E040-BB89AD436762","latestVersionIndicator":"Yes","beginDate":"2011-03-21","endDate":null,"createdBy":"BLABOLIJ","dateCreated":"2011-03-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"ACA0B1F3-8089-4383-E053-4EBD850A04CC","beginDate":"2020-08-11","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-08-11","modifiedBy":"ONEDATA","dateModified":"2020-08-11","deletedIndicator":"No"},{"value":"Bladder: Bladder Urothelial Carcinoma (BLCA)","valueDescription":"Bladder Urothelial Carcinoma","ValueMeaning":{"publicId":"6859301","version":"1","preferredName":"Bladder Urothelial Carcinoma","longName":"6859301","preferredDefinition":"The most common morphologic subtype of urinary bladder carcinoma (over 90% of cases).  It arises from the transitional epithelium.  It most often affects males in their sixth and seventh decades of life.  Hematuria is the most common symptom at presentation.  Pathologic stage is the strongest predictor of survival.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bladder Urothelial Carcinoma","conceptCode":"C39851","definition":"A carcinoma that arises from the urothelial lining of the bladder.  It is the most common morphologic type of urinary bladder carcinoma. It usually affects males in their sixth and seventh decades of life.  Hematuria is the most common symptom at presentation. Pathologic stage is the strongest predictor of survival.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"90A89662-E39B-6A17-E053-F662850A8154","latestVersionIndicator":"Yes","beginDate":"2019-08-22","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-08-22","modifiedBy":"ONEDATA","dateModified":"2019-08-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"ACA0B1F3-809E-4383-E053-4EBD850A04CC","beginDate":"2020-08-11","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-08-11","modifiedBy":"ONEDATA","dateModified":"2020-08-11","deletedIndicator":"No"},{"value":"Kidney: Clear Cell Renal Cell Carcinoma (CCRCC)","valueDescription":"Clear Cell Renal Cell Carcinoma","ValueMeaning":{"publicId":"3248533","version":"1","preferredName":"Clear Cell Renal Cell Carcinoma","longName":"3248533","preferredDefinition":"A malignant epithelial neoplasm of the kidney characterized by the presence of lipid-containing clear cells within a vascular network.  The tumor may metastasize to unusual sites and late metastasis is common.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Clear Cell Renal Cell Carcinoma","conceptCode":"C4033","definition":"A malignant epithelial neoplasm of the kidney characterized by the presence of lipid-containing clear cells within a vascular network.  The tumor may metastasize to unusual sites and late metastasis is common.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A6BBE041-B9CF-9503-E040-BB89AD435A00","latestVersionIndicator":"Yes","beginDate":"2011-06-27","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-06-27","modifiedBy":"COOPERM","dateModified":"2011-09-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"ACA0B1F3-80B3-4383-E053-4EBD850A04CC","beginDate":"2020-08-11","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-08-11","modifiedBy":"ONEDATA","dateModified":"2020-08-11","deletedIndicator":"No"},{"value":"Hematologic: Acute Myeloid Leukemia (AML)","valueDescription":"Acute Myeloid Leukemia","ValueMeaning":{"publicId":"4263972","version":"1","preferredName":"Acute Myeloid Leukemia","longName":"4263972","preferredDefinition":"A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues. The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities; 2) AML with multilineage dysplasia; 3) Therapy-related AML; 4) AML not otherwise categorized. The required bone marrow or peripheral blood blast percentage for the diagnosis of AML is 20% (WHO classification).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Myeloid Leukemia","conceptCode":"C3171","definition":"A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues. The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities; 2) AML with multilineage dysplasia; 3) Therapy-related AML; 4) AML not otherwise specified. The required bone marrow or peripheral blood blast percentage for the diagnosis of AML is 20% (WHO classification).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F63DCAA0-1110-5D4B-E040-BB89AD432C9C","latestVersionIndicator":"Yes","beginDate":"2014-04-04","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-04","modifiedBy":"KUMMEROA","dateModified":"2022-05-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"ADA369F2-F9B1-76CF-E053-4EBD850A07BE","beginDate":"2020-08-24","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-08-24","modifiedBy":"ONEDATA","dateModified":"2020-08-24","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008556","version":"1","preferredName":"Assessment Results","preferredDefinition":"the results of evaluations of the patient and the patient's disease.","longName":"ASSESS_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2D08DE9-38BB-7208-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"7385480","version":"1","preferredName":"Clinical Proteomic Tumor Analysis Consortium Neoplasm Type","preferredDefinition":"A national effort to accelerate the understanding of the molecular basis of cancer through the application of large-scale proteome and genome analysis, or proteogenomics.:A benign or malignant tissue growth resulting from uncontrolled cell proliferation. Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant cells exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia. Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias.:Something distinguishable as an identifiable class based on common qualities.","longName":"C157175:C3262:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Clinical Proteomic Tumor Analysis Consortium","conceptCode":"C157175","definition":"A national effort to accelerate the understanding of the molecular basis of cancer through the application of large-scale proteome and genome analysis, or proteogenomics.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Neoplasm","conceptCode":"C3262","definition":"A benign or malignant tissue growth resulting from uncontrolled cell proliferation. Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant cells exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia. Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AC9EAAE3-68A3-58C2-E053-4EBD850A8F9D","latestVersionIndicator":"Yes","beginDate":"2020-08-11","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-08-11","modifiedBy":"ONEDATA","dateModified":"2020-08-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"AC9EAAE3-68B4-58C2-E053-4EBD850A8F9D","latestVersionIndicator":"Yes","beginDate":"2020-08-11","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-08-11","modifiedBy":"KNABLEJ","dateModified":"2021-01-26","changeDescription":"1/26/21 jk Released per SME (NGM) review and approval. 8/24/20 jk Added AML PV for Procurement CRF.  8/11/19 jk created for CPTAC tumor procurement CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"6601273","version":"1","longName":"CPTAC (Clinical Proteomic Tumor Analysis Consortium)","context":"OCCPR","ClassificationSchemeItems":[{"publicId":"7409064","version":"1","longName":"All Procurement CRFs","context":"OCCPR"},{"publicId":"7409065","version":"1","longName":"Solid Tumor Specimen","context":"OCCPR"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Anticipated Tumor Type","type":"Preferred Question Text","description":"Anticipated Tumor Type","url":null,"context":"OCCPR"}],"origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"ADE3D055-FD28-5509-E053-4EBD850AF2F8","latestVersionIndicator":"Yes","beginDate":"2020-08-27","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-08-27","modifiedBy":"KNABLEJ","dateModified":"2021-01-26","changeDescription":"1/26/21 jk Released, upd Reg Status per SME (NGM) review and approval. 10/8/20 jk replaced system generated definition.  8/27/20 jk created for solid tumor procurement CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}